We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
Read MoreHide Full Article
Maravai LifeSciences Holdings, Inc. (MRVI - Free Report) , through its subsidiaries Cygnus Technologies and TriLink BioTechnologies, has announced the launch of AccuRes Host Cell DNA Quantification Kits. This latest launch blends Cygnus’ advanced extraction techniques with TriLink’s cutting-edge CleanAmp dNTPs technology. The AccuRes kits offer increased sensitivity and specificity in detecting host cell DNA, ensuring the production of biotherapeutics that meet and exceed the most rigorous regulatory standards.
Maravai LifeSciences, a leader in life sciences, drives innovation by providing critical products and services across nucleic acid synthesis, biologics safety testing and more. Its companies, Cygnus Technologies and TriLink BioTechnologies, play pivotal roles in the biopharmaceutical industry. Their combined efforts empower pharmaceutical leaders to meet the most pressing challenges in drug development and beyond.
Significance of MRVI’s AccuRes DNA Kits
The launch of AccuRes Host Cell DNA Quantification Kits by Maravai LifeSciences marks a significant advancement in biotherapeutic manufacturing. As the industry evolves toward more complex and precise drug formulations, the need for accurate monitoring of residual host cell DNA has become paramount.Regulatory standards require that host cell DNA levels stay within 10-100 pg per dose, necessitating a highly sensitive and accurate assay to monitor both in-process samples and final drug substances for lot release.
AccuRes kits, with their state-of-the-art probe-based quantification and compatibility with various qPCR instruments, offer a reliable and cost-effective solution for biopharmaceutical companies. By combining Cygnus' proprietary DNA extraction methods with TriLink’s patented CleanAmp dNTPs and a Hot Start Taq DNA Polymerase, these kits not only enhance assay performance but also ensure compliance with stringent regulatory requirements, ultimately contributing to safer and more effective production of biopharmaceuticals.
More on MRVI’s AccuRes Kits
The AccuRes Host Cell DNA kits utilize probe-based quantification to ensure high specificity for the target host cell line, avoiding the detection of off-target DNA. Featuring a FAM-labeled nucleic acid probe quenched by BHQ-1 until PCR extension, these kits are compatible with any qPCR instrument that detects FAM signals, reducing the need for additional equipment. The all-in-one kits include all necessary reagents for DNA extraction, PCR master mix, primers/probes, and DNA standards, offering exceptional sensitivity.
Market Prospects Favoring MRVI
Per a report in Coherent Market Insights, the DNA test kit market size is estimated to be worth $1.86 billion in 2024. It is anticipated to reach $5.4 billion by 2031, witnessing a CAGR of 16.4%.
The robust growth will be primarily fueled by heightened awareness of ancestry and origins, coupled with a surge in product launches that cater to this growing area of interest.
Recent Developments at Maravai Lifesciences
In May, TriLink BioTechnologies partnered with Johns Hopkins University to accelerate RNA therapeutics research and discovery. TriLink's investment in the center includes direct funding, technical expertise, and access to essential discovery and manufacturing supplies, all aimed at advancing mRNA development and lowering barriers to innovation in nucleic acid-based therapies.
In April, TriLink BioTechnologies signed a non-exclusive License and Supply Agreement with Lonza to expand access to TriLink’s CleanCap mRNA capping technologies. As demand for mRNA therapies grows, this partnership enables Lonza to incorporate TriLink's patented CleanCap analogs into its global mRNA development and manufacturing services, from pre-clinical stages through Phase III.
MRVI Stock Price Performance
Shares of Maravai LifeSciences have risen 39.8% so far this year compared with the industry’s 11.6% rise. The S&P 500 has witnessed a 17.8% rise in the same time frame.
Image Source: Zacks Investment Research
Favorable Earnings Surprise Trend
Maravai LifeSciences’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 116.67%.
Zacks Rank & Key Picks
Currently, Maravai LifeSciences carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and ABM Industries (ABM - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the industry’s 10.2% growth.
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% so far this year compared with the industry’s 11.9% growth.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
Maravai LifeSciences Holdings, Inc. (MRVI - Free Report) , through its subsidiaries Cygnus Technologies and TriLink BioTechnologies, has announced the launch of AccuRes Host Cell DNA Quantification Kits. This latest launch blends Cygnus’ advanced extraction techniques with TriLink’s cutting-edge CleanAmp dNTPs technology. The AccuRes kits offer increased sensitivity and specificity in detecting host cell DNA, ensuring the production of biotherapeutics that meet and exceed the most rigorous regulatory standards.
Maravai LifeSciences, a leader in life sciences, drives innovation by providing critical products and services across nucleic acid synthesis, biologics safety testing and more. Its companies, Cygnus Technologies and TriLink BioTechnologies, play pivotal roles in the biopharmaceutical industry. Their combined efforts empower pharmaceutical leaders to meet the most pressing challenges in drug development and beyond.
Significance of MRVI’s AccuRes DNA Kits
The launch of AccuRes Host Cell DNA Quantification Kits by Maravai LifeSciences marks a significant advancement in biotherapeutic manufacturing. As the industry evolves toward more complex and precise drug formulations, the need for accurate monitoring of residual host cell DNA has become paramount.Regulatory standards require that host cell DNA levels stay within 10-100 pg per dose, necessitating a highly sensitive and accurate assay to monitor both in-process samples and final drug substances for lot release.
AccuRes kits, with their state-of-the-art probe-based quantification and compatibility with various qPCR instruments, offer a reliable and cost-effective solution for biopharmaceutical companies. By combining Cygnus' proprietary DNA extraction methods with TriLink’s patented CleanAmp dNTPs and a Hot Start Taq DNA Polymerase, these kits not only enhance assay performance but also ensure compliance with stringent regulatory requirements, ultimately contributing to safer and more effective production of biopharmaceuticals.
More on MRVI’s AccuRes Kits
The AccuRes Host Cell DNA kits utilize probe-based quantification to ensure high specificity for the target host cell line, avoiding the detection of off-target DNA. Featuring a FAM-labeled nucleic acid probe quenched by BHQ-1 until PCR extension, these kits are compatible with any qPCR instrument that detects FAM signals, reducing the need for additional equipment. The all-in-one kits include all necessary reagents for DNA extraction, PCR master mix, primers/probes, and DNA standards, offering exceptional sensitivity.
Market Prospects Favoring MRVI
Per a report in Coherent Market Insights, the DNA test kit market size is estimated to be worth $1.86 billion in 2024. It is anticipated to reach $5.4 billion by 2031, witnessing a CAGR of 16.4%.
The robust growth will be primarily fueled by heightened awareness of ancestry and origins, coupled with a surge in product launches that cater to this growing area of interest.
Recent Developments at Maravai Lifesciences
In May, TriLink BioTechnologies partnered with Johns Hopkins University to accelerate RNA therapeutics research and discovery. TriLink's investment in the center includes direct funding, technical expertise, and access to essential discovery and manufacturing supplies, all aimed at advancing mRNA development and lowering barriers to innovation in nucleic acid-based therapies.
In April, TriLink BioTechnologies signed a non-exclusive License and Supply Agreement with Lonza to expand access to TriLink’s CleanCap mRNA capping technologies. As demand for mRNA therapies grows, this partnership enables Lonza to incorporate TriLink's patented CleanCap analogs into its global mRNA development and manufacturing services, from pre-clinical stages through Phase III.
MRVI Stock Price Performance
Shares of Maravai LifeSciences have risen 39.8% so far this year compared with the industry’s 11.6% rise. The S&P 500 has witnessed a 17.8% rise in the same time frame.
Image Source: Zacks Investment Research
Favorable Earnings Surprise Trend
Maravai LifeSciences’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 116.67%.
Zacks Rank & Key Picks
Currently, Maravai LifeSciences carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and ABM Industries (ABM - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the industry’s 10.2% growth.
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% so far this year compared with the industry’s 11.9% growth.